Analysis on Bacterial Distribution and Change of Drug Resistance Rate in ICUs Across Southwest China from 2018 to 2022
Fan Chang,Xiao Wang,Xiangning Huang,Xin Liu,Lijun Huang
DOI: https://doi.org/10.2147/IDR.S421357
2023-08-29
Infection and Drug Resistance
Abstract:Fan Chang, 1 Xiao Wang, 1 Xiangning Huang, 1 Xin Liu, 1 Lijun Huang 2 1 Department of Laboratory Medicine and Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, People's Republic of China; 2 West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, People's Republic of China Correspondence: Lijun Huang, West China School of Public Health and West China Fourth Hospital, Sichuan University, No. 18, Section 3, Renmin South Road, Wuhou District, Chengdu, Sichuan, People's Republic of China, Email Purpose: To analyze the distribution of bacteria and their drug resistance changes in Intensive Care Units (ICUs) across Southwest China from 2018 to 2022 and establish the antibiogram in this region to provide a basis for early empirical antimicrobial use. Methods: Non-repetitive pathogens isolated from 109 member units with qualified data were obtained from the Antimicrobial Resistance Surveillance System in Sichuan Province, southwest China. The results obtained were interpreted with reference to CLSI M100-31th, and analyzed with WHONET 5.6 software. Results: A total of 46,728 clinical isolates in ICUs were collected from 2018 to 2022, of which gram-negative organisms accounted for 76.1%, and gram-positive were 23.9%. The top 5 were Klebsiella pneumoniae, Acinetobacter baumannii , Escherichia coli , Pseudomonas aeruginosa and Staphylococcus aureus , respectively. From 2018 to 2022, the resistance rates of Klebsiella pneumoniae to imipenem and meropenem changed from 14.5% and 17.8% to 14.0% and 14.4%, showing a steady downward trend. Escherichia coli was always highly sensitive to carbapenems, with a total resistance rate of 3.8%. Among non-fermented gram-negative bacteria, the resistance rates of Pseudomonas aeruginosa to imipenem and meropenem decreased significantly, changed from 25.3% and 22.9% in 2018 to 20.0% and 15.1% in 2022. However, Acinetobacter baumannii showed high resistance rates of 76.2% and 76.9% to imipenem and meropenem, respectively. MRSA and MRCNS accounted for 31.7% and 82.7%, respectively. No vancomycin and linezolid-resistant Staphylococcus aureus was isolated. Enterococcus faecalis maintained high activity to vancomycin, teicoplanin, and linezolid; no vancomycin or teicoplanin-resistant Enterococcus faecium strains were detected. Conclusion: From 2018 to 2022, the isolated bacteria in ICU were mainly gram-negative bacteria, and the growth of some multidrug-resistant bacteria was effectively controlled. All levels of medical institutions should continue to strengthen bacterial resistance surveillance, promote the establishment of antimicrobial stewardship program, and enhance restrictions on outpatient antimicrobial use. Keywords: intensive care unit, bacterial resistance surveillance, multidrug-resistant bacteria, change of drug-resistant rate Antibiotic resistance, a growing global health problem, is one of the most important determinants of outcomes in patients with severe infections. 1–3 The World Health Organization (WHO) has warned that the misuse of antibiotics has resulted in a new elevation in the global antibiotic resistant rate, which further exacerbates the depletion of antibiotics. 4 Due to the emergence of drug-resistant bacteria, the treatment of clinical infectious diseases has faced more severe challenges, and meanwhile, the frequency of nosocomial infections is gradually increasing. Of the more than 700,000 medical-associated infections in the United States each year, more than half were caused by drug-resistant bacteria, and nearly half of the infections caused by drug-resistant bacteria were derived from intensive care unit (ICU). 5 Carbapenemase-resistant Enterobacteriaceae (CRE) bacteria has been spreading rapidly in Europe. 6,7 Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) have contributed to multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR), which has further provoked an increase in related infections within medical institutions. 8 As the rate of antibiotic resistance continues to rise, so do the morbidity, mortality, and treatment costs associated with infection among patients in healthcare settings, especially in the ICU setting. 9 Initial appropriate antibiotic therapy (IAAT) is a k -Abstract Truncated-
pharmacology & pharmacy,infectious diseases